As twin mental health and drug misuse crises kill thousands of people per week, the potential of psychedelic-assisted therapies “must be explored,” urges a federal letter on behalf of the U.S. health secretary and shared with The Intercept.
President Joe Biden’s administration “anticipates” that regulators will approve MDMA and psilocybin within the next two years for designated breakthrough therapies for PTSD and depression respectively. The administration is “exploring the prospect of establishing a federal task force to monitor” the emerging psychedelic treatment ecosystem, according to the letter sent by assistant secretary for mental health and substance use Miriam Delphin-Rittmon to Rep. Madeleine Dean, D-Pa.
But as evidence grows of the healing potential of certain controlled substances, including many hallucinogens, the war on drugs in the U.S. is steadily being wound down. Late Friday, the Drug Enforcement Agency dropped plans to schedule several DMT analogues after facing serious opposition, including a legal threat from companies Mindstate, Tactogen, and Panacea Plant Sciences. Full Story Link.
Friday was a great day for psychedelics. More generally, Friday was a great day for science and medicine, the rule of law and rational inquiry. This is because the DEA backed down on its clumsy attempt to ban five more psychedelic substances (tryptamines), which it had moved to place on Schedule I of the federal Controlled Substances Act. For Full Article Click Here.
Panacea Plant Sciences, a Washington State biotechnology company, has discovered formulations that act synergistically with dimethyltryptamine (DMT). The company announced the findings during the Cannabis Science Conference, on May 19. The data shows increases of more than 200% at the 5-HT2A receptor when the company's PPS1 and PPS2 drug candidates are combined with DMT. (For Full Article Click Here)
The latest preclinical results for PPS1 and PPS2 show synergistic activity at the 5-HT2A receptor when combined with dimethyltryptamine (DMT). PPS1 and PPS2 increased binding with DMT 224% and 16% respectively. The data indicates the ability of PPS drug candidates to make a sub-therapeutic dose of DMT potent enough to be potentially utilized for medical treatments. (For Full Article Click Here)
War on Drugs Update: DEA To Expand List of Banned Psychedelics
The stigma against psychedelics might appear to be fading, with psychedelic startups attracting billions of dollars of investment and the U.S. Food and Drug Administration (FDA) actively encouraging research into psilocybin and MDMA. But the war on psychedelic drugs is still alive and well over at the federal Drug Enforcement Agency (DEA).
The DEA announced earlier this month that they plan to add five more psychedelic drugs to the Controlled Substance Act, including at least one drug that is showing promise as a treatment for postpartum depression and treatment resistant depression.
Despite their medical potential, the DEA wants to add the drugs to Schedule 1 of the Controlled Substance Act, the most restrictive legal class of drugs that is reserved for substances with a high potential for abuse and no currently accepted medical use. The five compounds, all tryptamines, are:
DEA Proposes Adding 5 More Psychedelics to Schedule 1 Controlled Substances
Psychedelic research and medicine advocates have until February 14 to make the case that these five tryptamine hallucinogens do, in fact, have known medical use.
In a blow to the progressive psychedelics movement, the U.S. Drug Enforcement Agency (DEA) has proposed adding five more hallucinogenic compounds in schedule I of the Controlled Substances Act.
The regulator announced its intent last Friday to criminalize 4-Hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alphamethyltryptamine (5-MeO-AMT), N-Isopropyl-5-Methoxy-N-Methyltryptamine (5-MeO-MiPT), N,N-Diethyl-5-methoxytryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) not just for possession, distribution, import, export or manufacturing, but even research, instructional activities and chemical analysis.
)... (click the image for full article)
As the psychedelics industry matures, many companies in the field are being rewarded by the market with significant investments at impressive valuations for their efforts to medicalize, patent and mass produce psychedelic therapies.
A small but growing number of these companies are now launching programs to give back to the indigenous tribes whose traditional uses of psychedelics have been critical in shaping and influencing contemporary approaches to psychedelic substances.
The Farm Bill is due to be voted on again in 2022, and there are some significant updates that are expected to be included, like redefinitions of the term “THC”, limits on the amount of THC that can be in hemp, and more! Are you prepared for the potential changes that the hemp industry may face in the next couple of years? In this episode Founder of Panacea Plant Sciences and Ziese Farms, David Heldreth Jr., joins me for a candid discussion as we reflect on the past and present of the hemp industry. Click the image for the full podcast.
David Heldreth, Founder and CEO of Panacea Plant Sciences, discusses the rise in interest in psychedelic medicine and more.
Decades ago, a relentless campaign of stigma and misinformation was unleashed upon cannabis. By coming together and sharing our personal journeys as well as medical and scientific findings we have begun to reposition cannabis as a medicinal, natural product. Click the image for the full article.
Calls for increased production of Psilocybin, Mescaline, DMT, Bufotenine, Ibogaine, LSD
BELLEVUE, WASHINGTON, UNITED STATES, September 17, 2021 /EINPresswire.com/ -- Panacea Plant Sciences has asked the United States Drug Enforcement Administration to increase the production of several psychedelic drugs in recent comments to the agency.
On September 2 the DEA announced policy changes to increase the production of cannabis and psilocybin for research and development of medical therapies. This was part of an update to the overall plan for controlled substance research needs. Panacea Plant Sciences supports the DEA move to increase production for cannabis and psilocybin, but suggested the DEA increase production of: mescaline, DMT, bufotenine 5-MEO-DMT, ibogaine, LSD, and MDMA additionally.
Join Conley, Daniel, David, Carey and Dr. Martin Terry as they discuss the world of psychedelic research! Today the team discusses breakthrough laws that are being passed that allow scientists to discover new ways to heal the body and mind with psychedelics. Don't miss this far out episode! Available on Apple & Spotify. Click the image for the full podcast.
In this behind-the-scenes conversation we sit down with David Heldreth Jr. of Panacea Plant Sciences and Ziese Farms, based out of Washington, USA. Our conversation covered a lot of ground including the past, present and potential future of Cannabis and cannabinoid regulations, what people often misunderstand about rules regarding cannabinoids and other chemical constituents in foods, supplements, and cosmetics, how hemp companies should be preparing for the future of FDA, USDA, and DEA crackdowns, why regulations may be a thing to be celebrated rather than dismissed, what Hunter S. Thompson might have to say about the Cannabis industry, and much more! Click the image for the full podcast.
LOS ANGELES, Aug. 4, 2021 /PRNewswire/ -- Ziese Farms announces a hemp research partnership and patent licensing agreement with the Rodale Institute, a world leader and pioneer in organic farming.
Ziese Farms is a world leading hemp food company that has achieved first and only known allowances for the use of the hemp leaf for foods such as baby hemp greens. The company has developed IP and patent pending hemp cultivars, raw leaf foods, protein and other products. Ziese Farms believes in the power of the cannabis plant to supply the needs of humanity.
Ziese Farms granted Rodale Institute a license to the hemp/cannabis patents for use in research during the projects. Additionally, Panacea Plant Sciences, a cannabis biotech company, has licensed a patent for hemp cultivation to Rodale Institute and Ziese Farms for the research project. Click the image for the full article.
On June 23, Canada’s cannabis regulatory agency, Health Canada, released a private document requested under the Access to Information Act (AIA), that country’s version of the US government’s Freedom of Information Act.
The document in question was a 2020 safety study of the vape cartridge additive phytol. The study was conducted by Canopy Growth, one of Canada’s largest cannabis companies.
The data contained in that report has rocked the cannabis vaping world.
Phytol is a terpene that’s sometimes used to add flavor to vape cartridges, usually by adding it to a mix of cannabis oil and the common thinning agent propylene glycol.
The AIA request had been requested by David Heldreth, the former chief science officer of True Terpenes, a major phytol reseller. Heldreth’s friend Andrew Freedman, a Canadian citizen and vape expert, actually obtained the report. Click the image for the full article.
BELLEVUE, Wash., Feb. 18, 2021 /PRNewswire/ -- Panacea Plant Sciences announced that its first patent application for methods to manipulate the yield and growth of cannabis (hemp) plants (US20180279611) has been granted by the USPTO. The award comes at a pivotal moment as the company has recently begun meetings with the Environmental Protection Agency (EPA) to seek new product approvals. Click the image for the full article.
By David Downs - In 2019 and 2020, vaping-associated lung injuries killed 68 people and injured 2,807 across the United States. Read what happened, and what states are or aren't doing to make sure it doesn't happen again. Click the image for the full article.
Copyright © 2022 Panacea Plant Sciences - All Rights Reserved.